KODKodiak Sciences IncSigning up patients
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Macular Edema Secondary to Inflammation
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Jul 30, 2025
- Main results expected
- Apr 2027
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Mean change in BCVA
Measured over: Week 24
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06990399 · record last updated 2026-05-18 · checked 2026-11-09 15:47 UTC